TheStreet.com |
Galena Sacks CEO Amid Escalating Criminal Probe Into Fentanyl Drug Marketing
TheStreet.com The Feds are investigating Galena's marketing and promotional practices for Abstral, the company's fentanyl-based painkiller, according to an 8-K filing with the Securities and Exchange Commission. Schwartz was instrumental in Galena acquiring Abstral ... |
Tuesday, January 31, 2017
Galena Sacks CEO Amid Escalating Criminal Probe Into Fentanyl Drug Marketing - TheStreet.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment